DE602006021231D1 - Orale formulierung der wasserfreien olanzapin-form i - Google Patents

Orale formulierung der wasserfreien olanzapin-form i

Info

Publication number
DE602006021231D1
DE602006021231D1 DE602006021231T DE602006021231T DE602006021231D1 DE 602006021231 D1 DE602006021231 D1 DE 602006021231D1 DE 602006021231 T DE602006021231 T DE 602006021231T DE 602006021231 T DE602006021231 T DE 602006021231T DE 602006021231 D1 DE602006021231 D1 DE 602006021231D1
Authority
DE
Germany
Prior art keywords
olanzapine
core
salt
functional polymer
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006021231T
Other languages
English (en)
Inventor
Martin Ignacio Diez
Perez Carmen Ubeda
Alba Pablo Pablo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratorios Lesvi SL
Original Assignee
Laboratorios Lesvi SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38468505&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602006021231(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratorios Lesvi SL filed Critical Laboratorios Lesvi SL
Publication of DE602006021231D1 publication Critical patent/DE602006021231D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DE602006021231T 2005-12-26 2006-12-19 Orale formulierung der wasserfreien olanzapin-form i Active DE602006021231D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200503183A ES2279715B1 (es) 2005-12-26 2005-12-26 Formulacion oral de olanzapina.
US75410405P 2005-12-27 2005-12-27
PCT/EP2006/069905 WO2007074110A1 (en) 2005-12-26 2006-12-19 Oral formulation of anhydrous olanzapine form i

Publications (1)

Publication Number Publication Date
DE602006021231D1 true DE602006021231D1 (de) 2011-05-19

Family

ID=38468505

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006021231T Active DE602006021231D1 (de) 2005-12-26 2006-12-19 Orale formulierung der wasserfreien olanzapin-form i

Country Status (13)

Country Link
US (1) US8962018B2 (de)
EP (1) EP1965773B1 (de)
JP (1) JP2009521518A (de)
KR (1) KR20080080230A (de)
AT (1) ATE504292T1 (de)
CY (1) CY1111666T1 (de)
DE (1) DE602006021231D1 (de)
DK (1) DK1965773T3 (de)
ES (2) ES2279715B1 (de)
PL (1) PL1965773T3 (de)
PT (1) PT1965773E (de)
SI (1) SI1965773T1 (de)
WO (1) WO2007074110A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0522473D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
WO2012014012A1 (es) * 2010-07-27 2012-02-02 Laboratorios Andrómaco S.A. Procedimiento para preparar comprimidos de disolucion rapida oral que comprenden la forma i de olanzapina, los comprimidos obtenidos y su uso para el tratamiento de la esquizofrenia.
SI2612681T1 (sl) * 2010-08-31 2019-05-31 Toray Industries, Inc. Obložno sredstvo za farmacevtsko trdno obliko, farmacevtska filmska formulacija in obložena farmacevtska trdna oblika
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
CN104546807B (zh) * 2015-01-21 2020-09-01 齐鲁制药有限公司 奥氮平口腔速溶膜剂

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
CN1097619C (zh) 1994-07-12 2003-01-01 伯温德药品服务公司 隔潮膜涂层组合物及其生产方法以及涂层制品
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US5631250A (en) * 1995-03-24 1997-05-20 Eli Lilly And Company Process and solvate of 2-methyl-thieno-benzodiazepine
EG23659A (en) 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
JP2001501207A (ja) * 1996-09-24 2001-01-30 イーライ・リリー・アンド・カンパニー コーティングされた粒子製剤
US5843477A (en) * 1997-09-30 1998-12-01 Bayer Corporation Lubricants for use in tabletting
US7612112B2 (en) * 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US6906062B2 (en) 2001-12-24 2005-06-14 Sun Pharmaceutical Industries Limited Crystalline form I of 2-methyl-4-(4-menthyl-1-piperazinyl) 10H thieno [2,3-b][1,5]benzodiazepine
SI1476138T1 (sl) * 2002-02-21 2012-07-31 Valeant Internat Barbados Srl Formulacije s prirejenim sproščanjem vsaj ene oblike tramadola
PL196814B1 (pl) 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
EP1513846B1 (de) 2002-05-31 2011-03-02 Sandoz Ag Verfahren zur herstellung von olanzapin form i
SI21303A (sl) 2002-10-18 2004-04-30 Krka, Tovarna Zdravil, D.D.,, Novo Mesto Farmacevtska formulacija olanzapina
AU2003299983A1 (en) 2002-12-20 2004-07-22 St. James Associates Llc/Faber Research Series High pressure compaction for pharmaceutical formulations
WO2005009407A2 (en) 2003-07-29 2005-02-03 Ranbaxy Laboratories Limited Oral pharmaceutical formulations of olanzapine
AR047459A1 (es) * 2004-01-27 2006-01-18 Synthon Bv Sales estables de 2-metil-4-(4-metil-1-piperazinil)-10h-tieno[2,3-b][1,5]benzodiazepina (olanzapina)
ES2253091B1 (es) 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
GB0522474D0 (en) 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation

Also Published As

Publication number Publication date
EP1965773B1 (de) 2011-04-06
PT1965773E (pt) 2011-07-12
CY1111666T1 (el) 2015-10-07
DK1965773T3 (da) 2011-07-25
ES2279715A1 (es) 2007-08-16
WO2007074110A1 (en) 2007-07-05
KR20080080230A (ko) 2008-09-02
US8962018B2 (en) 2015-02-24
ES2359647T3 (es) 2011-05-25
SI1965773T1 (sl) 2011-09-30
US20080311203A1 (en) 2008-12-18
ATE504292T1 (de) 2011-04-15
ES2279715B1 (es) 2008-06-01
PL1965773T3 (pl) 2011-11-30
JP2009521518A (ja) 2009-06-04
EP1965773A1 (de) 2008-09-10

Similar Documents

Publication Publication Date Title
CY1111666T1 (el) Απο του στοματος συνθεση ανυδρης ολανζαπινης μορφης 1
CY1115150T1 (el) Βοηθηματα διαλυτοποιησης για τη χορηγηση πεπτιδιων απο το στομα, τα οποια περιεχουν διγουανιδη
NO20093146L (no) Amino-pyridinderivater som S1P1/EDG1-reseptoragonister
HN2006007884A (es) Derivados de oxiindol
TW200716202A (en) Pediatric formulation of topiramate
CO6290656A2 (es) Derivados heterociclicos de urea y metodos de uso de los mismos -211
PE20050286A1 (es) Formulacion de multiparticulas que comprenden oxicodona
CL2012000026A1 (es) Formulación farmacéutica acuosa que contiene una insulina, un análogo de insulina o un derivado insulínico, o una de sus sales farmacológicamente tolerables, y metionina; proceso para preparar dicha formulación; medicamento que la contiene; y su uso para tratar la diabetes mellitus.
DE602006012725D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
CL2008003789A1 (es) Compuestos derivados de bencimidazol sustituido por carboxilo o por hidroxilo, moduladores selectivos del receptor x de farnesoide (fxr); proceso de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, dislipidemia, sindrome metabolico, cancer, alzheimer.
BR112012018374A2 (pt) derivados de ácido carboxílico de pirrolidina ou tiazolidina, composição farmacêutica e métodos para uso no tratamento de distúrbios metabólicos como agonistas de receptor 43 acoplado à proteína g (gpr43).
CL2013001885A1 (es) Compuestos derivados de morfina, antagonistas del receptor ipiode periferico; composicion farmaceutica; formulacion oral; y uso para reducir los efectos colaterales de la terapia opioide (div. sol. 905-08).
NO20081250L (no) Kombinasjon av hypnotisk middel med langtidsvirkning og hypnotisk middel med korttidsvirkning, samt terapeutisk anvendelse av samme
WO2009123714A3 (en) Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
UA104902C2 (uk) Фармацевтичні композиції для запобігання зловживанню лікарськими препаратами
NO20075111L (no) Farmasoytisk sammensetning
NO20074933L (no) Farmasoytisk sammensetning som innbefatter et indolylmaleimidderivat
UA107353C2 (en) Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof
RS53363B (en) ORAL PHARMACEUTICAL TABLETS FOR THE CONTROLLED MESALAZINE RELEASE AND THE PROCESS OF OBTAINING THEM
DE602006015509D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
CL2011000044A1 (es) Uso de una composicion farmaceutica oral que comprende al menos un antagonista opioide seleccionado de naloxona, naltrexona, nalbufino o sus sales, adicionalmente puede comprender al menos un agonista opioide, tal como oxicodona, morfina u otros, para el tratamiento de la retencion urinaria.
ECSP10010664A (es) Derivados de urea heterocíclicos para el tratamiento de infecciones bacterianas
UY31839A (es) Compuestos
ATE451097T1 (de) Valsartanformulierungen
PE20071315A1 (es) Formulaciones de compuestos derivados de fenilo y procesos de preparacion para tabletas que contienen dichos compuestos